Capital Fund Management S.A. Buys New Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Capital Fund Management S.A. bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 28,058 shares of the company's stock, valued at approximately $1,083,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its holdings in shares of Protagonist Therapeutics by 4.5% during the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company's stock valued at $241,000 after buying an additional 270 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Protagonist Therapeutics by 1.4% during the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company's stock valued at $779,000 after buying an additional 278 shares during the period. Nisa Investment Advisors LLC lifted its stake in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after acquiring an additional 295 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock worth $1,112,000 after buying an additional 300 shares during the period. Finally, KBC Group NV boosted its holdings in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after purchasing an additional 737 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Price Performance

Shares of PTGX traded up $0.49 during mid-day trading on Monday, hitting $46.77. The stock had a trading volume of 63,701 shares, compared to its average volume of 842,867. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The firm has a market cap of $2.87 billion, a P/E ratio of 17.55 and a beta of 2.30. The business has a fifty day moving average price of $44.86 and a 200-day moving average price of $42.79.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings data on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. As a group, research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on PTGX. JMP Securities reaffirmed a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. Wedbush reaffirmed an "outperform" rating and set a $70.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, March 28th. Truist Financial upped their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. The Goldman Sachs Group decreased their price target on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, February 24th. Finally, BMO Capital Markets lifted their target price on Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a research report on Tuesday, March 11th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $65.44.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares of the company's stock, valued at $712,302.50. This trade represents a 23.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares in the company, valued at $20,627,126.80. This trade represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,776 shares of company stock valued at $3,585,010. 5.40% of the stock is currently owned by company insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.